Table 5.

Conditional logistic regression of risk of dementia divided by anti-gout preparations use days in different sex.

	N	No. of dementia	Crude OR	95% C.I.	p-value	Adjusted OR†	95% C.I.	p-value
Female Allopurinol (days)
None	1,016	505	1			1
<90	125	65	1.09	0.75–1.60	0.644	1.02	0.66–1.56	0.935
90–179	41	24	1.41	0.76–2.64	0.280	1.32	0.67–2.61	0.423
≥180	120	57	0.93	0.63–1.35	0.690	0.89	0.57–1.40	0.623
Benzbromarone (days)
None	348	181	1			1
<90	425	219	1.01	0.77–1.32	0.957	0.99	0.73–1.36	0.964
90–179	166	89	1.09	0.75–1.59	0.640	0.90	0.58–1.39	0.643
≥180	363	162	0.74	0.55–0.99	0.045	0.72	0.51–1.02	0.065
Sulfinpyrazone (days)
None	1,253	626	1			1
<90	19	9	0.90	0.37–2.21	0.819	1.10	0.41–2.98	0.847
≥90	30	16	1.14	0.56–2.34	0.715	1.49	0.64–3.44	0.353
Probenecid
None	1,289	644	1			1
Yes	13	7	1.17	0.39–3.47	0.782	1.34	0.40–4.48	0.631
Male Allopurinol (days)
None	1,312	640	1			1
<90	258	126	1.00	0.76–1.31	0.996	0.91	0.67–1.25	0.573
90–179	77	44	1.39	0.88–2.21	0.159	1.66	0.96–2.86	0.068
≥180	293	160	1.27	0.98–1.65	0.069	1.14	0.83–1.57	0.404
Benzbromarone (days)
None	443	245	1			1
<90	534	268	0.81	0.63–1.04	0.099	0.87	0.65–1.17	0.348
90–179	226	111	0.78	0.57–1.07	0.122	0.80	0.55–1.17	0.252
≥180	737	346	0.71	0.55–0.90	0.005	0.68	0.51–0.91	0.010
Sulfinpyrazone (days)
None	1,853	923	1			1
<90	38	21	1.24	0.65–2.34	0.517	1.56	0.74–3.31	0.246
≥90	49	26	1.14	0.64–2.05	0.655	1.36	0.70–2.64	0.364
Probenecid
None	1,925	959	1			1
Yes	15	11	2.75	0.88–8.64	0.083	1.75	0.51–6.02	0.372

^†Adjusted for allopurinol, benzbromarone, sulfinpyrazone, probenecid, hypertension, hyperlipidemia, chronic liver disease, chronic kidney disease, diabetes, COPD, autoimmune disease, cardiovascular disease, stroke, depression, parkinson's disease, warfarin, and statin.